US panel gives nod to GSK/Genmab's Arzerra for leukaemia
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline/Genmab's anti-CD20 monoclonal antibody Arzerra (ofatumumab) is reasonably likely to have a clinical benefit in heavily pretreated patients with chronic lymphocytic leukaemia (CLL), the US FDA's outside advisors say.